Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Postsynthetic Strategy for Oligonucleotides Containing 2-Fluoro-adenine and Isoguanine Nucleobases.

Organic letters·2026
Same author

Mapping the evolution of sepsis and intestinal epithelial barrier research: a bibliometric analysis (1977-2024).

Journal of thoracic disease·2026
Same author

MKRN1 suppresses cuproptosis in colorectal cancer through ubiquitin-dependent regulation of SLC31A1.

Biological procedures online·2026
Same author

Impact of Subretinal Drusenoid Deposits on Ellipsoid Zone-Related Thickness Metrics.

Investigative ophthalmology & visual science·2026
Same author

4-Octyl itaconate attenuates renal calculi formation by inhibiting ferroptosis and oxidative stress via the Nrf2-HO-1/SLC7A11 axis.

European journal of pharmacology·2026
Same author

From targeted delivery to inflammation suppression: engineering plant exosomes for heart failure therapy post-infarction.

Materials today. Bio·2026

Related Experiment Video

Updated: May 22, 2025

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.0K

Modulation of TTR gene expression in the eye using modified siRNAs.

Jiaxin Hu1, Xin Gong2, Jayanta Kundu3

  • 1Departments of Pharmacology and Biochemistry, UT Southwestern Medical Center, Dallas, TX 75390, United States.

Nucleic Acids Research
|May 19, 2025
PubMed
Summary

Lipid-modified small interfering RNAs (siRNAs) effectively inhibit transthyretin (TTR) gene expression in the eye via intravitreal injection. This approach offers a promising strategy for treating ocular manifestations of TTR amyloidosis.

More Related Videos

Loss-of-Function Approach in the Embryonic Chick Retina by Using Tol2 Transposon-Mediated Transgenic Expression of Artificial microRNAs
06:58

Loss-of-Function Approach in the Embryonic Chick Retina by Using Tol2 Transposon-Mediated Transgenic Expression of Artificial microRNAs

Published on: May 18, 2022

978
Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research
10:10

Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research

Published on: November 2, 2018

9.2K

Related Experiment Videos

Last Updated: May 22, 2025

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.0K
Loss-of-Function Approach in the Embryonic Chick Retina by Using Tol2 Transposon-Mediated Transgenic Expression of Artificial microRNAs
06:58

Loss-of-Function Approach in the Embryonic Chick Retina by Using Tol2 Transposon-Mediated Transgenic Expression of Artificial microRNAs

Published on: May 18, 2022

978
Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research
10:10

Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research

Published on: November 2, 2018

9.2K

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Drug Delivery

Background:

  • Small interfering RNAs (siRNAs) are established therapeutics for liver gene silencing.
  • Transthyretin (TTR) amyloidosis affects the eye, necessitating ocular TTR gene expression reduction.
  • Current systemic siRNA therapies target liver TTR expression, but ocular delivery remains a challenge.

Purpose of the Study:

  • To investigate the efficacy of lipid-modified siRNAs for inhibiting TTR gene expression in the eye.
  • To evaluate intravitreal injection as a local delivery method for ocular siRNA therapy.
  • To explore the potential of siRNA-based therapies for treating ocular TTR amyloidosis.

Main Methods:

  • Development and formulation of pyrimidine C5- and 2'-O-linked lipid-modified siRNAs in saline.
  • Administration of lipid-modified siRNAs via intravitreal injection in an ocular model.
  • Assessment of TTR gene expression inhibition in ocular tissues.
  • Comparison of lipid-modified siRNAs with GalNAc-modified siRNAs for ocular delivery.

Main Results:

  • Pyrimidine C5- and 2'-O-linked lipid-modified siRNAs successfully inhibited TTR gene expression in the eye following intravitreal administration.
  • Lipid chain length and accessibility were identified as factors influencing in vivo silencing efficacy.
  • GalNAc-modified siRNAs also demonstrated TTR inhibition, though with lower potency compared to lipid-modified versions.
  • Demonstrated widespread inhibition of TTR expression throughout ocular tissues.

Conclusions:

  • Lipid-modified siRNAs delivered via intravitreal injection are effective for inhibiting ocular TTR gene expression.
  • This approach holds significant potential for treating the ocular complications associated with TTR amyloidosis.
  • Lipid-siRNA conjugates represent a versatile platform for developing novel ocular drug delivery strategies.